Frexalimab (anti-CD40L) - Primary antibody, specific to CD40LG, Human IgG1
Specifications & Purity
Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥95%(SDS-PAGE&SEC), Lot by Lot
Biochemical and Physiological Mechanisms
Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL-4. Involved in immunoglobulin class switching. Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, actin polymerization,
Frexalimab (anti-CD40L) is a monoclonal antibody targeting the CD40 ligand (CD40L). Frexalimab (anti-CD40L) has the potential for multiple sclerosis research.
Product Properties
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
145.66 kDa
Purification Method
Protein A purified
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
2515463-86-0
Images
Frexalimab (anti-CD40L) (Ab182964) - Flow Cytometry Flow Cytometry analysis of unstimulated (left) or 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated (right) Jurkat cells labelling CD40L (red) with Frexalimab (anti-CD40L) (Ab182964) at 0.1 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Frexalimab (anti-CD40L) (Ab182964) - SEC The purity of Frexalimab (anti-CD40L) (Ab182964) is more than 95% verified by HPLC.
Frexalimab (anti-CD40L) (Ab182964) - ELISA Immobilized Recombinant Human CD40 Ligand/TNFSF5 protein (rp189423) at 1.0 μg/mL can bind Frexalimab (anti-CD40L) (Ab182964) with the EC
₅₀
of 16.93 ng/mL.
